Provided by Tiger Trade Technology Pte. Ltd.

Scholar Rock Holding Corp

42.20
0.0000
Post-market: 42.12-0.0800-0.19%19:30 EDT
Volume:3.30M
Turnover:139.40M
Market Cap:5.14B
PE:-12.56
High:43.12
Open:41.87
Low:41.12
Close:42.20
52wk High:61.76
52wk Low:27.07
Shares:121.79M
Float Shares:107.73M
Volume Ratio:1.82
T/O Rate:3.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3601
EPS(LYR):-3.4845
ROE:-167.77%
ROA:-58.82%
PB:20.25
PE(LYR):-12.11

Loading ...

Scholar Rock downgraded to Equal Weight from Overweight at Barclays

TIPRANKS
·
Sep 15

Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook

Reuters
·
Sep 15

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid AI Pullback

MT Newswires Live
·
Sep 14

Scholar Rock Says Its First Muscle-Targeted SMA Therapy Will Cost About $310,000 Annually

Reuters
·
Sep 14

Wedbush Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)

TIPRANKS
·
Sep 14

Scholar Rock Holding Price Target Maintained with a $64.00/Share by Wedbush

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Scholar Rock Exec Says Its First Drug to Target Muscle Loss in Spinal Mus­Cu­Lar at­Ro­Phy Has a Wholesale Acquisition Cost of $11,659 for a Single Use Vial - Conf.call

THOMSON REUTERS
·
Sep 14

Scholar Rock Exec Says Co Expects the Annual Net Cost in the U.S. for a Typical Patient to be Approximately $310,000

THOMSON REUTERS
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Top Premarket Gainers

MT Newswires Live
·
Sep 14

Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating

MT Newswires Live
·
Sep 14

Scholar Rock Shares up 11.6% Premarket After FDA Nod for First Muscle-Targeted Drug for Type of Genetic Disease

THOMSON REUTERS
·
Sep 14

Scholar Rock Holding Corporation : Citigroup Raises Target Price to $74 from $60

THOMSON REUTERS
·
Sep 14

Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

TIPRANKS
·
Sep 14

Scholar Rock announces FDA approval of isembyld

TIPRANKS
·
Sep 12

FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy Patients Aged 2 and Older on SMN2 Therapy

Reuters
·
Sep 12

Scholar Rock Holding Corporation - Isembyld U.S. Commercial Launch Underway; Product Available to Ship in Coming Days

THOMSON REUTERS
·
Sep 12

Scholar Rock Announces FDA Approval of Isembyld™ (Apitegromab-Mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (Sma)

THOMSON REUTERS
·
Sep 12